These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 35079034)

  • 1. Predicting clinical outcomes of cancer patients with a p53 deficiency gene signature.
    Schaafsma E; Takacs EM; Kaur S; Cheng C; Kurokawa M
    Sci Rep; 2022 Jan; 12(1):1317. PubMed ID: 35079034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TP53 mutations, expression and interaction networks in human cancers.
    Wang X; Sun Q
    Oncotarget; 2017 Jan; 8(1):624-643. PubMed ID: 27880943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
    Manzano RG; Catalan-Latorre A; Brugarolas A
    BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A P53-Deficiency Gene Signature Predicts Recurrence Risk of Patients with Early-Stage Lung Adenocarcinoma.
    Zhao Y; Varn FS; Cai G; Xiao F; Amos CI; Cheng C
    Cancer Epidemiol Biomarkers Prev; 2018 Jan; 27(1):86-95. PubMed ID: 29141854
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects of TP53 mutational status on gene expression patterns across 10 human cancer types.
    Parikh N; Hilsenbeck S; Creighton CJ; Dayaram T; Shuck R; Shinbrot E; Xi L; Gibbs RA; Wheeler DA; Donehower LA
    J Pathol; 2014 Apr; 232(5):522-33. PubMed ID: 24374933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer type-dependent correlations between TP53 mutations and antitumor immunity.
    Li L; Li M; Wang X
    DNA Repair (Amst); 2020 Apr; 88():102785. PubMed ID: 32007736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas.
    Donehower LA; Soussi T; Korkut A; Liu Y; Schultz A; Cardenas M; Li X; Babur O; Hsu TK; Lichtarge O; Weinstein JN; Akbani R; Wheeler DA
    Cell Rep; 2019 Jul; 28(5):1370-1384.e5. PubMed ID: 31365877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition.
    Mak MP; Tong P; Diao L; Cardnell RJ; Gibbons DL; William WN; Skoulidis F; Parra ER; Rodriguez-Canales J; Wistuba II; Heymach JV; Weinstein JN; Coombes KR; Wang J; Byers LA
    Clin Cancer Res; 2016 Feb; 22(3):609-20. PubMed ID: 26420858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression signatures of TP53 mutations in serous ovarian cancers.
    Bernardini MQ; Baba T; Lee PS; Barnett JC; Sfakianos GP; Secord AA; Murphy SK; Iversen E; Marks JR; Berchuck A
    BMC Cancer; 2010 May; 10():237. PubMed ID: 20504346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TP53 mutations as potential prognostic markers for specific cancers: analysis of data from The Cancer Genome Atlas and the International Agency for Research on Cancer TP53 Database.
    Li VD; Li KH; Li JT
    J Cancer Res Clin Oncol; 2019 Mar; 145(3):625-636. PubMed ID: 30542790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma.
    Sun H; Liu SY; Zhou JY; Xu JT; Zhang HK; Yan HH; Huan JJ; Dai PP; Xu CR; Su J; Guan YF; Yi X; Yu RS; Zhong WZ; Wu YL
    EBioMedicine; 2020 Oct; 60():102990. PubMed ID: 32927274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics.
    Wheler JJ; Janku F; Naing A; Li Y; Stephen B; Zinner R; Subbiah V; Fu S; Karp D; Falchook GS; Tsimberidou AM; Piha-Paul S; Anderson R; Ke D; Miller V; Yelensky R; Lee JJ; Hong D; Kurzrock R
    Mol Cancer Ther; 2016 Oct; 15(10):2475-2485. PubMed ID: 27466356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an Arf
    Chapeau EA; Gembarska A; Durand EY; Mandon E; Estadieu C; Romanet V; Wiesmann M; Tiedt R; Lehar J; de Weck A; Rad R; Barys L; Jeay S; Ferretti S; Kauffmann A; Sutter E; Grevot A; Moulin P; Murakami M; Sellers WR; Hofmann F; Jensen MR
    Proc Natl Acad Sci U S A; 2017 Mar; 114(12):3151-3156. PubMed ID: 28265066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significance of
    Hou Y; Tan S; Wang G
    Genet Test Mol Biomarkers; 2021 May; 25(5):346-354. PubMed ID: 33956533
    [No Abstract]   [Full Text] [Related]  

  • 15. Unequal prognostic potentials of p53 gain-of-function mutations in human cancers associate with drug-metabolizing activity.
    Xu J; Wang J; Hu Y; Qian J; Xu B; Chen H; Zou W; Fang JY
    Cell Death Dis; 2014 Mar; 5(3):e1108. PubMed ID: 24603336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of public cancer datasets and signatures identifies TP53 mutant signatures with robust prognostic and predictive value.
    Lehmann BD; Ding Y; Viox DJ; Jiang M; Zheng Y; Liao W; Chen X; Xiang W; Yi Y
    BMC Cancer; 2015 Mar; 15():179. PubMed ID: 25886164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [TP53 mutations and molecular epidemiology].
    Otsuka K; Ishioka C
    Gan To Kagaku Ryoho; 2007 May; 34(5):683-9. PubMed ID: 17496437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significance of
    Chen Y; Zhao W; Bi F; Pan X; Yin L; Zhao C
    Oxid Med Cell Longev; 2022; 2022():1817339. PubMed ID: 35847579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutated
    Li AM; Boichard A; Kurzrock R
    Cancer Biol Ther; 2020; 21(1):95-100. PubMed ID: 31564192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inactivation of the INK4a/ARF locus and p53 in sporadic extrahepatic bile duct cancers and bile tract cancer cell lines.
    Caca K; Feisthammel J; Klee K; Tannapfel A; Witzigmann H; Wittekind C; Mössner J; Berr F
    Int J Cancer; 2002 Feb; 97(4):481-8. PubMed ID: 11802210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.